Skip to Content

    Hengrui, which made $2.5 billion in sales last year, invests twice as much as any other pharma in R&D, and its investments are paying off: It’s China’s largest pharmaceutical company and a leader in innovation. China’s plan to bulk-purchase generic drugs in 2020 will drive down industry prices, but analysts say only 1% to 2% of Jiangsu’s revenue will be impacted, while competitors in its peer group will be more exposed.

    Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score2.1
    Sector
    Health Care
    Industry
    Pharmaceuticals
    CEO
    Sun Piaoyang
    Websitehttps://www.hrs.com.cn
    HQ Location
    Lianyungang, China
    Country
    China
    Revenues ($M) (Past 12 Months)$2,884
    Profits ($M) (Past 12 Months)$669
    Market Value as of Oct. 9, 2019 ($M)$48,796
    Employees21,016

    Refinitiv Sustainable Leadership Monitor